- Home
- Publications
- Publication Search
- Publication Details
Title
Tackling COVID-19 with neutralizing monoclonal antibodies
Authors
Keywords
monoclonal antibody, COVID-19, neutralization, SARS-CoV-2, therapeutics
Journal
CELL
Volume 184, Issue 12, Pages 3086-3108
Publisher
Elsevier BV
Online
2021-05-27
DOI
10.1016/j.cell.2021.05.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations
- (2021) Rakesh Sarkar et al. ARCHIVES OF VIROLOGY
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
- (2021) C. Garrett Rappazzo et al. SCIENCE
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
- (2021) Lewis F. Buss et al. SCIENCE
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- Process and Operations Strategies to Enable Global Access to Antibody Therapies
- (2021) Brian Kelley et al. BIOTECHNOLOGY PROGRESS
- Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
- (2021) Emma C. Thomson et al. CELL
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- (2021) Zhuoming Liu et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
- (2021) Gabriele Cerutti et al. Cell Host & Microbe
- Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
- (2021) Ester C Sabino et al. LANCET
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- SARS-CoV-2 evolution during treatment of chronic infection
- (2021) Steven A. Kemp et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Sixteen novel lineages of SARS-CoV-2 in South Africa
- (2021) Houriiyah Tegally et al. NATURE MEDICINE
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
- (2021) Nicholas G. Davies et al. SCIENCE
- Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
- (2021) Kevin R. McCarthy et al. SCIENCE
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
- (2021) Alexander Muik et al. SCIENCE
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
- (2021) Naveenchandra Suryadevara et al. CELL
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
- (2021) Matthew McCallum et al. CELL
- Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
- (2021) Xianding Deng et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients – propensity-score matched case-control study
- (2021) Adam Tworek et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
- (2021) Dan Frampton et al. LANCET INFECTIOUS DISEASES
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
- (2021) Nicholas G. Davies et al. NATURE
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
- (2021) Lawrence Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- Broadly neutralizing antibodies for HIV-1 prevention and therapy
- (2021) Boris Julg et al. SEMINARS IN IMMUNOLOGY
- Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study
- (2021) Mark S Graham et al. Lancet Public Health
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection
- (2020) Jeremy J Lim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Developing therapeutic monoclonal antibodies at pandemic pace
- (2020) Brian Kelley NATURE BIOTECHNOLOGY
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
- (2020) Meng Yuan et al. SCIENCE
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
- (2020) Qianqian Li et al. CELL
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2020) Wafaa B. Alsoussi et al. JOURNAL OF IMMUNOLOGY
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2
- (2020) Ann M. Arvin et al. NATURE
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
- (2020) M. Pamela Griffin et al. NEW ENGLAND JOURNAL OF MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
- (2020) Hongjing Gu et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
- (2020) Andrew Rambaut et al. Nature Microbiology
- Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
- (2020) Shuo Du et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
- (2020) Stylianos Bournazos et al. NATURE
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Structures and distributions of SARS-CoV-2 spike proteins on intact virions
- (2020) Zunlong Ke et al. NATURE
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Neuropilin-1 is a host factor for SARS-CoV-2 infection
- (2020) James L. Daly et al. SCIENCE
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
- (2020) Ludovico Cantuti-Castelvetri et al. SCIENCE
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
- (2020) Erik Volz et al. CELL
- Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
- (2020) Victoria A. Avanzato et al. CELL
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
- (2020) Allison J. Greaney et al. Cell Host & Microbe
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
- (2020) Alexandra Schäfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
- (2020) Bina Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
- (2019) Ellie Hershberger et al. EBioMedicine
- Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
- (2019) Alexandra C. Walls et al. CELL
- Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
- (2019) Marina Caskey et al. NATURE MEDICINE
- Novel correlates of protection against pandemic H1N1 influenza A virus infection
- (2019) Sophia Ng et al. NATURE MEDICINE
- Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways
- (2019) Polina Weitzenfeld et al. JOURNAL OF CLINICAL INVESTIGATION
- A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
- (2019) Aimin Tang et al. Nature Communications
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin
- (2018) Michael B. Doud et al. Nature Communications
- Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza
- (2018) S. Omar Ali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination therapy with anti-HIV-1 antibodies maintains viral suppression
- (2018) Pilar Mendoza et al. NATURE
- The influenza virus hemagglutinin head evolves faster than the stalk domain
- (2018) Ericka Kirkpatrick et al. Scientific Reports
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
- (2017) Qing Zhu et al. Science Translational Medicine
- Tackling influenza with broadly neutralizing antibodies
- (2017) Davide Corti et al. Current Opinion in Virology
- Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes
- (2016) Nicole L. Kallewaard et al. CELL
- Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
- (2016) David J. DiLillo et al. JOURNAL OF CLINICAL INVESTIGATION
- Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
- (2016) Alexandra C. Walls et al. NATURE
- HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
- (2016) T. Schoofs et al. SCIENCE
- Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors
- (2016) Daniel F. Ortiz et al. Science Translational Medicine
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
- (2014) John Mair-Jenkins et al. JOURNAL OF INFECTIOUS DISEASES
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
- (2014) Sung-Youl Ko et al. NATURE
- Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo
- (2014) David J DiLillo et al. NATURE MEDICINE
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
- (2013) Dan H. Barouch et al. NATURE
- Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
- (2011) Qing Zhu et al. JOURNAL OF INFECTIOUS DISEASES
- Coronaviruses
- (2011) Mark R. Denison et al. RNA Biology
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
- (2009) X. Carbonell-Estrany et al. PEDIATRICS
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Palivizumab: where to from here?
- (2008) Georgiana Georgescu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now